<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423121</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00144766</org_study_id>
    <nct_id>NCT03423121</nct_id>
  </id_info>
  <brief_title>A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis</brief_title>
  <official_title>A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to identify the safety and tolerability of bile acid supplementation in&#xD;
      patients with progressive Multiple Sclerosis (MS). Participants will also be assessed for an&#xD;
      impact of the bile acid on their immune system and gut microbiome. Half of the participants&#xD;
      will receive the bile acid tauroursodeoxycholic acid (TUDCA) and half will receive placebo.&#xD;
      The investigators believe participants who take TUDCA will have normalization of blood bile&#xD;
      acid levels, a normalization of abnormal immune response and a normalization of the gut&#xD;
      microbiome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-related adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <description>Safety and tolerability will be assessed based on treatment-related adverse events in the two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Change in fasting bile acid levels in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Change in composition of the gut microbiota assessed using shot-gun metagenomic sequencing in first morning stool specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Change in flow cytometric assessments of peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Change in physical and mental health scores as assessed using the Multiple Sclerosis Quality of Life-54 (MSQOL-54) instrument. This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. Two summary scores - physical health and mental health - are derived from a weighted combination of scale scores. Higher scores suggest a better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>TUDCA Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tauroursodeoxycholic Acid</intervention_name>
    <description>Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.</description>
    <arm_group_label>TUDCA Treatment</arm_group_label>
    <other_name>Taurolite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Participants will be given four capsules of the placebo twice daily.</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Progressive MS based on Lublin Criteria&#xD;
&#xD;
          -  Low bile acid levels identified using targeted metabolomics analysis&#xD;
&#xD;
          -  On the same therapy for the past 6 months and not expected to switch therapy in the&#xD;
             next 6 months&#xD;
&#xD;
          -  No relapse in the past 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No previous history of liver disease or cholecystectomy&#xD;
&#xD;
          -  No stage IV/V chronic kidney disease or other severe metabolic derangements (e.g.&#xD;
             poorly controlled thyroid disease or diabetes)&#xD;
&#xD;
          -  BMI &lt; 15 kg/m2 and BMI &gt; 40 kg/m2&#xD;
&#xD;
          -  Female patients who are pregnant or nursing, or not willing to use contraception&#xD;
&#xD;
          -  Chronic antibiotic use&#xD;
&#xD;
          -  Corticosteroid treatment within the past 30 days&#xD;
&#xD;
          -  Known history of other neuroinflammatory, neurodegenerative or systemic autoimmune&#xD;
             disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavan Bhargava, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesse Ritter, MHS</last_name>
    <phone>410-502-2488</phone>
    <email>jritte15@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Ritter, MHS</last_name>
      <phone>410-502-2488</phone>
      <email>jritte15@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodoxicoltaurine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

